ArticleBarrier immunity2026
Integrative Omics Analysis Reveals a CD206
Article in Barrier immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
RNA sequencing (RNA-seq) analysis revealed transcriptional features indicative of sustained immunosuppression within regulatory T cells (Tregs) isolated from atherosclerotic tissues, highlighting the critical contribution of immune checkpoint (ICP) receptor-ligand interactions to atherosclerosis progression. To comprehensively characterize the roles of ICP signaling in this context, we integrated transcriptomic profiling, quantitative RT-PCR, and flow cytometry analysis, yielding several key findings: (1) Multiomics integration revealed global transcriptomic alterations in ICP receptors and ligands across diverse tissues, immune cell types, and disease stages in both human and murine models of atherosclerosis; (2) Several ICP components demonstrated functional relevance, including dual-function ligand CD155 (PVR); inhibitory ligands Lgals3 and Itgb1; stimulatory ligands Tnfrsf9 and CD48; and inhibitory receptors Havcr2 and Lair1. These molecules act as microenvironmental sensors, dynamically responding to atherosclerotic cues; (3) Experimental validation confirmed upregulation of the CD155-TIGIT axis within immune cells of atherosclerotic plaques. Notably, CD155 expression positively correlated with CD206 expression in both CD11b
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.